Читать книгу Biologics, Biosimilars, and Biobetters - Группа авторов - Страница 36

Generics and Biosimilars Initiative (GaBi/GaBI) was founded in 2008. The mission of GaBI is to foster the efficient use of high quality and safe medicines at an affordable price, thus advancing and supporting the idea of accessible, affordable, and sustainable health care internationally.

GaBI aims to raise the scientific status of SMD generics and biosimilar medicines and to provide comprehensive high‐quality, scientifically sound, reliable, well‐documented, and up‐to‐date information about generics and biosimilar medicines in both print and electronic media in an open‐access format. To this end, GaBI provides a service for healthcare providers to support them in making cost‐effective choices when it comes to treatment option decisions. Physicians and pharmacists are the primary target of GaBI, followed by healthcare policymakers and drug regulators, third‐party insurers, and pharmaceutical/ biotech industry.⁶³ This initiative has GaBI Online and GaBI Journal as its principal resources.